Table 2.
Univariate and multivariate analysis of risk to death in COVID-19 patients.
| Characteristic | Events/Number at Risk | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | ||
| Age | |||||
| <65 years | 277/441 | Reference (A) | |||
| ≥65 years | 165/240 | 1.3 (0.93–1.82) | 0.1213 | ||
| Sex | |||||
| Male | 206/307 | Reference (B) | |||
| Female | 236/374 | 0.84 (0.61–1.15) | 0.2768 | ||
| Comorbidities | |||||
| Heart Disease | 101/143 | 1.39 (0.93–2.07) | 0.1075 | ||
| Diabetes | 70/104 | 1.14 (0.73–1.77) | 0.5771 | ||
| Neurologic disease | 9/13 | 1.22 (0.37–4.01) | 0.7418 | ||
| Chronic lung disease | 19/29 | 1.03 (0.47–2.25) | 0.9439 | ||
| Nephropathy | 29/39 | 1.61 (0.77–3.36) | 0.2066 | ||
| Southeast Brazilian Region | 261/419 | 0.74 (0.53–1.03) | 0.0712 | 0.74 (0.53–1.03) | 0.0777 |
| Clinical Stage | |||||
| I/II | 61/106 | Reference (C) | |||
| III/IV | 293/444 | 1.43 (0.93–2.21) | 0.1039 | ||
| Unknown | 21/34 | 1.19 (0.54–2.63) | 0.6642 | ||
| Other | 67/97 | 1.65 (0.93–2.94) | 0.0903 | ||
| Mult. Drug Regimen | 238/369 | 0.96 (0.7–1.32) | 0.8094 | ||
| Drug Class | |||||
| Anti-Metabolic | 175/265 | 1.09 (0.79–1.5) | 0.6210 | ||
| Microtubule inhibitor | 154/239 | 0.97 (0.7–1.35) | 0.8501 | ||
| Alkylating | 95/168 | 0.62 (0.44–0.89) | 0.0092 | ||
| Cisplatin | 216/313 | 1.4 (1.02–1.92) | 0.0388 | ||
| Type 1 topois. inhib. | 29/46 | 0.92 (0.49–1.71) | 0.7842 | ||
| Type 2 topois. inhib. | 69/134 | 0.5 (0.34–0.73) | 0.0003 | 0.55 (0.36–0.85) | 0.0070 |
| Chemotherapy setting | |||||
| Neoadj./Definit./Adjuv. | 94/170 | Reference (D) | |||
| Palliative 1st Line | 209/298 | 1.9 (1.28–2.81) | 0.0013 | 1.83 (1.22–2.74) | 0.0038 |
| Palliative 2nd Line | 43/58 | 2.32 (1.2–4.49) | 0.0127 | 2.26 (1.15–4.45) | 0.0180 |
| Hematological cancer | 96/155 | 1.32 (0.84–2.05) | 0.2253 | 1.68 (1.05–2.7) | 0.0310 |
| Primary Site | |||||
| GI | 126/199 | Reference (E) | |||
| Head and Neck | 18/35 | 0.61 (0.3–1.26) | 0.1852 | ||
| Lung | 38/51 | 1.69 (0.85–3.39) | 0.1360 | ||
| Others | 25/29 | 3.62 (1.21–10.81) | 0.0212 | ||
| Breast | 51/90 | 0.76 (0.46–1.26) | 0.2832 | ||
| Gynecological | 55/75 | 1.59 (0.89–2.87) | 0.1201 | ||
| Prostate | 13/17 | 1.88 (0.59–5.99) | 0.2838 | ||
| Cent. Nervous Syst. | 7/12 | 0.81 (0.25–2.65) | 0.7288 | ||
| Hematologic | 96/155 | 0.94 (0.61–1.46) | 0.7898 | ||
| Sarcomas | 13/18 | 1.51 (0.52–4.4) | 0.4534 | ||
| Active chemotherapy | 265/431 | 0.66 (0.47–0.92) | 0.0144 | 0.66 (0.46–0.93) | 0.0169 |
Abbreviations: Adjuv: Adjuvant; Definit: Definitive; GI: Gastrointestinal; Inhib: Inhibitor; Mult.: Multiple; Neoadj: Neoadjuvant; Topois: Topoisomerase. (A) Patients with less than 65 years were used as reference to calculate the OR for patients with more than 65 years (characteristic: Age), (B): Male patients were used as reference to calculate the OR for female patients (characteristic: Sex), (C): Patients with clinical stage I/II were used as reference to calculate the OR for III/IV, unknown and others patients (characteristic: Clinical stage), (D): Neoadj./Definit./Adjuv. were used as reference to calculate the OR for Palliative 1st Line, Palliative 2nd Line and Hematological cancer (characteristic: Chemotherapy objective), (E): Patients with GI cancers were used as reference to calculate the OR for head and neck, lung, others, breast gynecological, prostate, central nervous system, hematologic and sarcomas (characteristic: Primary site).